Adjuvant chemotherapy given during and after pelvic radiation for high-risk endometrial cancer improves failure-free, but not overall, survival at five years and may be discussed as an alternative to radiation alone.
A combination regimen involving standard carboplatin chemotherapy and a novel drug may improve overall survival for more than 50% of women with high-grade serous ovarian cancers, according to research published in Precision Oncology (published online May 2017; doi:10.1038/s41698-017-0008-z).
Common comorbidities such as hypertension, heart disease, and diabetes may contribute to a woman’s prognosis after being diagnosed with ovarian cancer, according to a study published in Cancer Causes Control (2017;28:469-486).
Women with stage II-IV low-grade serous carcinoma of the ovary or peritoneum who received hormonal maintenance therapy after primary treatment had longer progression-free survival (PFS) compared with women who underwent routine observation after primary treatment.
Primary cytoreductive surgery (PCS) is better than neoadjuvant chemotherapy (NACT) for overall survival in women aged 70 years or younger with advanced-stage epithelial ovarian cancer (EOC), according to a recent study published in JAMA Oncology.